Literature DB >> 2577147

P-fimbriae vaccines. II. Cross reactive protection against pyelonephritis.

J A Roberts1, M B Kaack, G Baskin, T K Korhonen, S B Svenson, J Winberg.   

Abstract

Protection against acute pyelonephritis was induced by immunization of baboons with purified P-fimbriae of Escherichia coli as vaccines. To test for cross-protective capacity of two different P-fimbriae vaccines we vaccinated baboons with P-fimbriae purified from either E. coli strain ER2 or strain JR1 and subsequently challenged the animals with E. coli strain JR1. All vaccinated animals showed elevated antibody titers to P-fimbriae from both of the E. coli strains used. Both vaccines tended to reduce the time of bacteriuria. They partially prevented pyelonephritis and protected against loss of renal function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577147     DOI: 10.1007/bf00850213

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  20 in total

1.  Natural history of urinary infection in adults.

Authors:  L R Freedman
Journal:  Kidney Int Suppl       Date:  1975-08       Impact factor: 10.545

2.  P-fimbriae vaccines. I. Cross reactive antibodies to heterologous P-fimbriae.

Authors:  M B Kaack; A Pere; T K Korhonen; S B Svenson; J A Roberts
Journal:  Pediatr Nephrol       Date:  1989-10       Impact factor: 3.714

3.  Prevention of pyelonephritis by immunization with P-fimbriae.

Authors:  J A Roberts; K Hardaway; B Kaack; E N Fussell; G Baskin
Journal:  J Urol       Date:  1984-03       Impact factor: 7.450

4.  Observations on the pathogenic properties of the K88, Hly and Ent plasmids of Escherichia coli with particular reference to porcine diarrhoea.

Authors:  H W Smith; M A Linggood
Journal:  J Med Microbiol       Date:  1971-11       Impact factor: 2.472

5.  Experimental pyelonephritis in the monkey. VII. Ascending pyelonephritis in the absence of vesicoureteral reflux.

Authors:  J A Roberts; G M Suarez; B Kaack; G Kallenius; S B Svenson
Journal:  J Urol       Date:  1985-06       Impact factor: 7.450

6.  Experimental pyelonephritis in the monkey. III. Pathophysiology of ureteral malfunction induced by bacteria.

Authors:  J A Roberts
Journal:  Invest Urol       Date:  1975-09

7.  Experimental pyelonephritis. V. Functional characteristics of pyelonephritis.

Authors:  K L Janson; J A Roberts
Journal:  Invest Urol       Date:  1978-03

8.  Maternal immunization with P fimbriae for the prevention of neonatal pyelonephritis.

Authors:  M B Kaack; J A Roberts; G Baskin; G M Patterson
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

Review 9.  Does kidney infection cause renal failure?

Authors:  C M Kunin
Journal:  Annu Rev Med       Date:  1985       Impact factor: 13.739

10.  Immunology of pyelonephritis in the primate model. V. Effect of superoxide dismutase.

Authors:  J A Roberts; J K Roth; G Domingue; R W Lewis; B Kaack; G Baskin
Journal:  J Urol       Date:  1982-12       Impact factor: 7.450

View more
  6 in total

1.  Attenuation of antibody response to acute pyelonephritis by treatment with antibiotics.

Authors:  D E Neal; M B Kaack; G Baskin; J A Roberts
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

2.  Protective anti-idiotype antibodies in the primate model of pyelonephritis.

Authors:  M B Kaack; L N Martin; S B Svenson; G Baskin; R H Steele; J A Roberts
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

3.  The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract.

Authors:  J A Roberts; B I Marklund; D Ilver; D Haslam; M B Kaack; G Baskin; M Louis; R Möllby; J Winberg; S Normark
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

4.  Prevention of renal scarring from pyelonephritis in nonhuman primates by vaccination with a synthetic Escherichia coli serotype O8 oligosaccharide-protein conjugate.

Authors:  J A Roberts; M B Kaack; G Baskin; S B Svenson
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

Review 5.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

Review 6.  Management of primary vesico-ureteric reflux in children--operation ineffective in preventing progressive renal damage.

Authors:  J Winberg
Journal:  Infection       Date:  1994       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.